Oral-ATO for TP53-mutated Myeloid Malignancies
Oral-ATO for TP53-mutated Myeloid Malignancies
Recruiting · NCT06778187 · Registry updated 2025-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral-ATO for TP53-mutated Myeloid Malignancies | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2025-06-10 | NCT06778187 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The University of Hong Kong | 349 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Queen Mary Hospital, Hong Kong | Hong Kong | Hong Kong | 4 |